Vivus (VVUS) is raising the bar on erectile dysfunction drugs potentially becoming the latest formidable competitor to Viagra and Cialis in the $3.8 billion market. Investors in the California-based pharmaceutical company jumped on Wednesday when the company cited positive results from a late-stage study of its erectile dysfunction drug avanafil. The stock shot up almost 6% in early morning trading while shares of Pfizer (PFE) which makes Viagra and Eli Lilly (LLY) maker of Cialis remained relatively flat. Vivus announced the results from its phase 3 Revive study which tested the safety and efficacy of avanafil for the treatment ...

U.S. stocks are higher Monday as a report of robust economic growth in Japan sparks a rally in energy and materials issues.

Bristol-Myers Squibb and Merck & Co. led drugs stocks higher early Monday, echoing trading in the broader market.

Because I’ve been feeling a little under the weather yesterday morning I bought a 64-ounce bottle of cranberry juice. Much to the dismay (and possibly awe) of my co-workers I drank the entire thing in about three hours’ time. My goal was to shake my head cold. The good news is it worked but if I never drink another glass of cranberry juice again it will be fine by me. Asian stocks took a breather overnight. The Hang Seng and the Nikkei were off 1.01% and 0.68% respectively. European stocks however were up a smidge early this morning. And ...

After a six-session win streak for the Dow Jones Industrial Average, U.S. stocks open modestly lower after a disappointing holiday outlook from Wal-Mart and pressure on the energy and utilities sectors.

More Than Half of Industry Executives Anticipate Multiple Deals Next Year

Persistent Lipid Effects Remained in the Higher Dose Arms After Cessation Of Therapy in Patients with Dyslipidemia